CAMs as counter measures against infectious and inflammatory disease

CAM 作为对抗传染病和炎症性疾病的对策

基本信息

  • 批准号:
    8302174
  • 负责人:
  • 金额:
    $ 115.26万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-09-30 至 2014-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): CAMs are used for the prevention and treatment of infectious and inflammatory diseases, though for many of these CAMs, their true efficacy and the molecular basis for their purported benefits have not been defined and/or confirmed. We propose a new Center of Excellence for Research on CAMs (CERC) focused on the study of the mechanisms of action of diverse CAMs in models of pulmonary and intestinal infectious disease. Since in many instances the resulting inflammatory response associated with infection in the lung and intestinal track accounts for the actual pathology in the disease, we also intend to expand ongoing efforts in using CAMs to minimize inflammation induced tissue damage. The ultimate goal of this CERC is to provide critical insight into the mechanisms of action of select CAMs that can be used as countermeasures against emerging and select agents that infect the pulmonary and intestinal mucosa. This Center brings together scientists with expertise in bacterial and viral diseases of the lung and intestinal tract, study of CAM effects on innate leukocytes and epithelial cells, purification of defined agonists from crude plant extracts, use of probiotic CAMs, and use of rodent models of infectious and inflammatory disease to define specific mechanisms of action. This Center will also take advantage of new BSL-3 facilities to study the impact of CAMs on select agents. The CERC will initially be focused on three distinct projects, which will be supported by two Cores: Administrative (Core A) and Animal Model (Core B). The three Research Projects are: Project 1) CAMs that enhance ??T cell function, Project Leader, Mark Jutila, Ph.D.; Project 2) Anti-viral CAMs, Project Leader, Dr. Michele Hardy, Ph.D.; and Project 3) Anti-inflammatory microbial CAMs and arthritis, Project Leader, Dr. David Pascual, Ph.D. The Animal Models Core will serve as a unique and highly interactive resource, facilitating synergy and collaboration between the three research projects.
描述(由申请人提供):CAM用于预防和治疗感染性和炎性疾病,尽管对于许多这些CAM,其真正的疗效和其声称的益处的分子基础尚未被定义和/或证实。我们提出了一个新的卓越中心的研究CAM(CERC)的重点是不同的CAM在肺部和肠道传染病模型的作用机制的研究。由于在许多情况下,与肺部和肠道感染相关的炎症反应导致了疾病的实际病理学,因此我们还打算扩大使用CAM的持续努力,以最大限度地减少炎症诱导的组织损伤。该CERC的最终目标是提供对选择CAM的作用机制的关键见解,这些CAM可用作对抗感染肺和肠粘膜的新出现和选择因子的对策。该中心汇集了在肺部和肠道的细菌和病毒疾病,CAM对先天性白细胞和上皮细胞的影响,从天然植物提取物中纯化确定的激动剂,使用益生菌CAM,以及使用感染性和炎症性疾病的啮齿动物模型来确定特定作用机制方面具有专业知识的科学家。该中心还将利用新的BSL-3设施来研究CAM对特定代理人的影响。CERC最初将集中在三个不同的项目上,这三个项目将由两个核心支持:管理(核心A)和动物模型(核心B)。这三个研究项目是:项目1)CAM,提高??T细胞功能,项目负责人,Mark Jutila博士;项目2)抗病毒CAMs,项目负责人,Dr. Michele哈代,Ph.D.;和项目3)抗炎微生物CAM和关节炎,项目负责人,大卫帕斯夸尔博士,博士。动物模型核心将作为一个独特的和高度互动的资源,促进三个研究项目之间的协同作用和合作。

项目成果

期刊论文数量(10)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Immunomodulatory and hemagglutinating activities of acidic polysaccharides isolated from Combretum racemosum.
  • DOI:
    10.1016/j.intimp.2013.01.015
  • 发表时间:
    2013-03
  • 期刊:
  • 影响因子:
    5.6
  • 作者:
    Schepetkin IA;Kouakou K;Yapi A;Kirpotina LN;Jutila MA;Quinn MT
  • 通讯作者:
    Quinn MT
Aging influences the response of T cells to stimulation by the ellagitannin, oenothein B.
  • DOI:
    10.1016/j.intimp.2015.04.008
  • 发表时间:
    2015-06
  • 期刊:
  • 影响因子:
    5.6
  • 作者:
    Ramstead AG;Schepetkin IA;Todd K;Loeffelholz J;Berardinelli JG;Quinn MT;Jutila MA
  • 通讯作者:
    Jutila MA
Milk-based nutraceutical for treating autoimmune arthritis via the stimulation of IL-10- and TGF-β-producing CD39+ regulatory T cells.
  • DOI:
    10.1371/journal.pone.0117825
  • 发表时间:
    2015
  • 期刊:
  • 影响因子:
    3.7
  • 作者:
    Maddaloni M;Kochetkova I;Jun S;Callis G;Thornburg T;Pascual DW
  • 通讯作者:
    Pascual DW
Immunomodulatory activity of polysaccharides isolated from Alchornea cordifolia.
  • DOI:
    10.1016/j.jep.2012.12.037
  • 发表时间:
    2013-03-07
  • 期刊:
  • 影响因子:
    5.4
  • 作者:
    Kouakou, Koffi;Schepetkin, Igor A.;Yapi, Ahoua;Kirpotina, Liliya N.;Jutila, Mark A.;Quinn, Mark T.
  • 通讯作者:
    Quinn, Mark T.
Immunomodulatory activity of polysaccharides isolated from Clerodendrum splendens: beneficial effects in experimental autoimmune encephalomyelitis.
  • DOI:
    10.1186/1472-6882-13-149
  • 发表时间:
    2013-06-28
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Kouakou K;Schepetkin IA;Jun S;Kirpotina LN;Yapi A;Khramova DS;Pascual DW;Ovodov YS;Jutila MA;Quinn MT
  • 通讯作者:
    Quinn MT
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Mark A Jutila其他文献

Mark A Jutila的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Mark A Jutila', 18)}}的其他基金

Development of novel, safe and efficacious Coxiella burnetii vaccine
新型、安全、有效的伯氏柯克斯体疫苗的研制
  • 批准号:
    8952597
  • 财政年份:
    2015
  • 资助金额:
    $ 115.26万
  • 项目类别:
Role of type I IFN and human TLR4 in Coxiella burnetii pathogenesis
I 型 IFN 和人 TLR4 在伯氏柯克斯体发病机制中的作用
  • 批准号:
    9195688
  • 财政年份:
    2015
  • 资助金额:
    $ 115.26万
  • 项目类别:
Role of Toll-like receptors in Coxiella burnetii infection
Toll样受体在伯氏柯克斯体感染中的作用
  • 批准号:
    8302673
  • 财政年份:
    2012
  • 资助金额:
    $ 115.26万
  • 项目类别:
Role of Toll-like receptors in Coxiella burnetii infection
Toll样受体在伯氏柯克斯体感染中的作用
  • 批准号:
    8546297
  • 财政年份:
    2012
  • 资助金额:
    $ 115.26万
  • 项目类别:
MT VET COBRE II CORE B: CELLULAR ANALYSIS CORE
MT VET COBRE II 核心 B:细胞分析核心
  • 批准号:
    8360159
  • 财政年份:
    2011
  • 资助金额:
    $ 115.26万
  • 项目类别:
MT VET COBRE II CORE B: CELLULAR ANALYSIS CORE
MT VET COBRE II 核心 B:细胞分析核心
  • 批准号:
    8168413
  • 财政年份:
    2010
  • 资助金额:
    $ 115.26万
  • 项目类别:
MT VET COBRE CORE C: CELL ANALYSIS CORE
MT VET COBRE 核心 C:细胞分析核心
  • 批准号:
    7960523
  • 财政年份:
    2009
  • 资助金额:
    $ 115.26万
  • 项目类别:
Enhancement of Innate Immunity Against Coxiella Pneumonia
增强针对柯克斯体肺炎的先天免疫
  • 批准号:
    7675558
  • 财政年份:
    2009
  • 资助金额:
    $ 115.26万
  • 项目类别:
MT VET COBRE CORE C: CELL ANALYSIS CORE
MT VET COBRE 核心 C:细胞分析核心
  • 批准号:
    7721023
  • 财政年份:
    2008
  • 资助金额:
    $ 115.26万
  • 项目类别:
CAMs as counter measures against infectious and inflammatory disease
CAM 作为对抗传染病和炎症性疾病的对策
  • 批准号:
    7574619
  • 财政年份:
    2008
  • 资助金额:
    $ 115.26万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 115.26万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 115.26万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 115.26万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 115.26万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 115.26万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 115.26万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 115.26万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 115.26万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 115.26万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 115.26万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了